Fig. 2

Tofacitinib suppresses Th17 cells, ILC1s, and GM-CSF⁺ ILCs in the lung. a Frequencies of CD4⁺ T cell subsets in the lung of control mice (n = 5) and tofacitinib-treated mice (n = 5). b ILC subsets in the lung of control mice (n = 5) and tofacitinib-treated mice (n = 5). c DCs and macrophages in the lung of control mice (n = 5) and tofacitinib-treated mice (n = 5). Data are shown as the mean ± SEM. *P < 0.05, Mann-Whitney U tests